Payment overview · 2025
General Payments
$188.96
11 reported records · 7 companies
Healthcare provider profile · identity verified
Louis B Harris, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOLIVAR, MO · NPI 1922018076
Verified facts
What the public records show
CMS Open Payments records show Louis B Harris, M.D. received $188.96 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Arexvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.42 | 28.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.22 | 19.7% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $34.27 | 18.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.80 | 9.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.01 | 9.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.36 | 8.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.88 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.96 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.42 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.42 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
46 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 69 |
| Lisinopril | Lisinopril | 317 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 68 |
| Gabapentin | Gabapentin | 290 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 49 |
| Eliquis | Apixaban | 229 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 57 |
| Losartan Potassium | Losartan Potassium | 190 | 39 |
| Potassium Chloride | Potassium Chloride | 185 | 38 |
| Montelukast Sodium | Montelukast Sodium | 169 | 33 |
| Tramadol Hcl | Tramadol Hcl | 161 | 40 |
| Jardiance | Empagliflozin | 144 | 29 |
| Buspirone Hcl | Buspirone Hcl | 140 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 42 |
| Metformin Hcl Er | Metformin Hcl | 122 | 31 |
| Bumetanide | Bumetanide | 117 | 24 |
| Furosemide | Furosemide | 113 | 23 |
| Carvedilol | Carvedilol | 111 | 16 |
| Spironolactone | Spironolactone | 110 | 27 |
| Januvia | Sitagliptin Phosphate | 99 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 99 | 20 |
| Omeprazole | Omeprazole | 93 | 20 |
| Famotidine | Famotidine | 90 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 20 |
| Trandolapril | Trandolapril | 84 | 23 |
| Klor-Con M20 | Potassium Chloride | 83 | 13 |
| Lorazepam | Lorazepam | 81 | 25 |
| Trazodone Hcl | Trazodone Hcl | 81 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 79 | 13 |
| Mirtazapine | Mirtazapine | 78 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 21 |
| Allopurinol | Allopurinol | 76 | 19 |
| Metformin Hcl | Metformin Hcl | 76 | 16 |
| Meloxicam | Meloxicam | 70 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 18 |
| Telmisartan | Telmisartan | 66 | 16 |
| Donepezil Hcl | Donepezil Hcl | 63 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 62 | 14 |
| Estradiol | Estradiol | 61 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 61 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | suppressed |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Baclofen | Baclofen | 57 | suppressed |
| Topiramate | Topiramate | 57 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 16 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 46 | 46 |
| Spiriva Handihaler | Tiotropium Bromide | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 11 |
| Simvastatin | Simvastatin | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Fentanyl | Fentanyl | 43 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 40 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 38 | 15 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Qulipta | Atogepant | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Prednisone | Prednisone | 23 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 14 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Savella | Milnacipran Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.96 · 11 records | ABBVIE INC. | ARISTADA, EVENITY, LYBALVI, Leqembi, Ozempic, PROLIA, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, UZEDY, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error